abrdn

FOR IMMEDIATE RELEASE

For More Information Contact:

abrdn U.S. Closed-End Funds Investor Relations 800-522-5465 Investor.Relations@abrdn.com

ABRDN LIFE SCIENCES INVESTORS (HQL) ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS

(Philadelphia, June 26, 2024) – <u>abrdn Life Sciences Investors ("HQL")</u> announced today the results of the Annual Meeting of Shareholders (the "Meeting"), held on June 25, 2024.

As of the record date, April 1, 2024, HQL had outstanding 27,350,517 shares of common stock. 87.84% of outstanding common stock were voted representing a quorum.

Shareholders approved the election of two Class B Trustees to the Board to serve until 2027 Annual Meeting by the following votes:

	Number of Votes Cast For	Percentage of Votes Cast For	Number of Votes Cast Against/Withheld	Percentage of Votes Cast Against / Withheld
Stephen Bird	20,269,963	84.4%	3,753,701	15.6%
Jeffrey Bailey	19,670,734	81.9%	4,352,930	18.1%

Shareholders opposed a shareholder proposal regarding annual terms of trustees by the following votes:

Number of Votes Cast For	Percentage of Votes Cast For	Number of Votes Cast Against/Withheld	<u>Votes Cast</u>	Number of Votes Abstained	Percentage of Votes Abstained
6,891,241	41.6%	9,133,348	55.1%	533,327	3.3%

In the United States, abrdn is the marketing name for the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, abrdn Asia Limited, and abrdn ETFs Advisors LLC.

Closed-end funds are traded on the secondary market through one of the stock exchanges. A Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund's portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not guarantee future results.

www.abrdnhql.com